Bacterial-derived blis for treatment of acne

Abstract

This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bacteriocide or bacteriostat for acne-causing bacteria, namely P. acnes.

What is claimed is: 
     
         1 . A method of treating acne of a subject, comprising administering to said subject, an effective amount of a bacteriocin-like inhibitory substance (BLIS), thereby treating said acne. 
     
     
         2 . The method of  claim 1 , wherein the BLIS is isolated from  S. salivarius, S. pyogenes, L. salivarius  or a combination thereof. 
     
     
         3 . The method of  claim 2 , wherein the bacterium is  S. salivarius.    
     
     
         4 . The method of  claim 3 , wherein the BLIS is SAL A2, SAL B, or a combination thereof. 
     
     
         5 . The method of  claim 2 , wherein the bacterium is  S. pyogenes  and the BLIS is Streptin A1 
     
     
         6 . The method of  claim 2 , wherein the bacterium is  L. salivarius  and the BLIS is Salivacin 140, ABP-118, or a combination thereof. 
     
     
         7 . The method of  claim 3 , wherein the composition further comprises BLIS derived from  S. aureus, P. acnes, B. melaninogenicus,  or a combination thereof. 
     
     
         8 . The method of  claim 1 , further comprising coadministering to said subject an additional agent, wherein the agent is isotrenitoin, Benzoyl peroxide, topical retinoid, spironolactone, an oral contraceptive or a combination thereof. 
     
     
         9 . The method of  claim 1 , wherein the acne-causing bacteria is resistant to erythromycin, tetracycline, doxycycline, minocycline, oxytetracycline clindamycin, or a combination thereof. 
     
     
         10 . A method of treating acne of a subject, comprising administering to said subject an effective amount of a pharmaceutical preparation comprising a bacteriocin-like inhibitory substance (BLIS), whereby said BLIS is bacteriocidal or bacteriostatic for said acne-causing bacteria thereby treating said acne 
     
     
         11 . The method according to  claim 10 , wherein said administering comprises orally administering to said subject a liquid or solid formulation containing said pharmaceutical preparation. 
     
     
         12 . The method according to  claim 10 , wherein said administering comprises topically administering to said subject a formulation containing said pharmaceutical preparation. 
     
     
         13 . The method according to  claim 10 , wherein said administering comprises administering to said subject a formulation containing said pharmaceutical preparation, wherein said formulation is a food formulation. 
     
     
         14 . The method of  claim 13 , wherein said food formulation is a yoghurt culture. 
     
     
         15 . The method according to  claim 10 , wherein said administering comprises administering to said subject a formulation containing said pharmaceutical preparation, wherein said formulation is a probiotic capsule. 
     
     
         16 . The method of  claim 10 , further comprising a pharmaceutically acceptable carrier, excipient, flow agent, processing aid, a diluent or a combination thereof. 
     
     
         17 . The method of  claim 16 , wherein said carrier, excipient, lubricant, flow agent, processing aid, diluent or a combination thereof, is a gum, a starch, a sugar, a cellulosic material, an acrylate, calcium carbonate, magnesium oxide, talc, lactose monohydrate, magnesium stearate, colloidal silicone dioxide or mixtures thereof. 
     
     
         18 . The method of  claim 10 , wherein said pharmaceutical preparation is in the form of a pellet, a tablet, a capsule, a solution, a suspension, a dispersion, an emulsion, an elixir, a gel, an ointment, a cream, a foam or a suppository. 
     
     
         19 . The method of  claim 10 , wherein said pharmaceutical preparation is a liquid dosage form. 
     
     
         20 . The method of  claim 10 , wherein said pharmaceutical preparation is a solid dosage form. 
     
     
         21 . The method of  claim 10 , wherein treating is preventing, reducing incidence of, inhibiting, reducing symptoms or their severity or a combination thereof. 
     
     
         22 . A method of suppressing, inhibiting the growth of, or killing a  P. acnes  bacteria comprising the step of contacting said bacteria with a bacteriocin-like inhibiting substance (BLIS), wherein said BLIS is a bacteriocide or a bacteriostat of  P. acnes.